E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild to moderate active plaque psoriasis despite topical psoriasis treatment |
|
E.1.1.1 | Medical condition in easily understood language |
Mild to moderate active plaque psoriasis despite topical psoriasis treatment |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050576 |
E.1.2 | Term | Psoriasis vulgaris |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective:
To assess the value of the ‘Topical Treatment Optimising Programme’ in the topical treatment of insufficiently treated mild to moderate psoriasis after 8 weeks of once daily treatment with Daivobet® Gel.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives:
To assess the value of the ‘Topical Treatment Optimising Programme’ in the topical treatment of insufficiently treated mild to moderate psoriasis every 8 weeks over a treatment period of 64 weeks.
To assess the usefulness of a ‘Topical Therapy Questionnaire’, a ‘Patient Preference Questionnaire’ and ‘Patient’s self Global Assessment’ in the assessment of patient reported outcomes and in comparison to available tools.
To assess the value of the ‘Topical Treatment Optimising Programme’ in country-specific subanalyses.
To compare the drop-out rates after 64 weeks of treatment between the study arms (‘Topical Treatment Optimising Programme’ versus ‘non- Topical Treatment Optimising Programme’).
To compare the consumption of Daivobet® Gel between the study arms.
To confirm long term efficacy and safety of the study medication.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male and female patients aged at least 18 years
- Mild to moderate active plaque psoriasis with a PGA ≥ 2 on the 7 point scale by Langley and Ellis and a Body Surface Area (BSA) of ≤ 10%
- Topical psoriasis treatment with coal or tar preparations, tazarotene, steroids, or vitamin D analogues, or combinations of steroids and vitamin D analogues (except gel combination products containing 50 micrograms calcipotriol / 0.5 mg betamethasone/g) or dithranol and its combination preparations over the last 8 weeks prior to Visit 1 (week 0)
- Written informed consent to participate in the study has been given prior to any study related procedures
|
|
E.4 | Principal exclusion criteria |
- Severe renal insufficiency
- Severe hepatic disorders
- Known hyper calcaemia
- Erythrodermic, exfoliative, pustular or guttate psoriasis
- Facial or genital psoriasis
- Fulfilment of at least one contraindication according to the Summary of Product Characteristics of Daivobet®
- Pregnant and/or breast-feeding women or women of childbearing potential who do not agree to use one of the following contraceptive methods for the duration of the study and at least 1 week after the last dose of study medication: Intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)
- Hypersensitivity to the active substances or to any of the excipients
- Suspected non-compliance with the clinical study procedures
- Current participation in another clinical study
- Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to Visit 1 (week 0):
• etanercept – within 4 weeks prior to Visit 1 (week 0)
• adalimumab, alefacept, infliximab – within 2 months prior to Visit 1 (week 0)
• ustekinumab – within 4 months prior to Visit 1 (week 0)
• experimental products – within 4 weeks/5 half-lives (whichever is longer) prior to Visit 1 (week 0)
- Phototherapy within the following time periods prior to Visit 1 (week 0):
• PUVA – within 4 weeks prior to Visit 1 (week 0)
• UV-B – within 2 weeks prior to Visit 1 (week 0)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Rate of patients with a PGA (as defined by Langley and Ellis 2004) of 0 or 1 at week 8 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Rate of patients with a PGA (as defined by Langley and Ellis 2004) of 0 or 1 at weeks 16 to 64 (documented at intervals of 8 weeks)
Mean PGA and BSA at weeks 8 to 64 (documented at intervals of 8 weeks)
EQ-5D, EQ-VAS and DLQI at weeks 0, 8, 32 and 64
Rate of patients achieving DLQI ≤ 5 at weeks 0, 8, 32 and 64
Exploratory Patient Reported Outcomes: TTQ, PPQ and PsGA at weeks 0, 8, 32 and 64
Results of TTOP element ranking by the patient (only TTOP intervention arm) at weeks 8 and 64
Rate of patients reaching a PsGA score of 0 or 1 at weeks 8 to 64 in the single countries (documented at intervals of 8 weeks)
Days away from work/studies due to psoriasis
Mean weight of returned study medication at weeks 4 to 64 (documented at intervals of 4 to 8 weeks)
Drop-out rate per study arm at week 64
Rates of AEs and SAEs
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Throughout the study from week 0 to week 64 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Improvement of patient compliance |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 130 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |